close

Enter

Log in using OpenID

and health - Consorzio Technapoli

embedDownload
Horizon 2020
Health/biotech/ict opportunities
Caterina BUONOCORE
NCP Sfida Sociale 1,
Health, wellbeing , Dem. Change.
APRE
AGENDA
1.Horizon 2020: opportunità per la Salute
e il piano di lavoro per la Sfida Sociale 1
2014-2015
2. Novità, regole di partecipazione e
criteri di valutazione
3. Elementi per una proposta di successo
in H2020
2
Struttura basata su tre pilatri interconnessi.
Health, demographic change
and wellbeing
Food security, sustainable
agriculture, marine and
maritime research & the
bioeconomy
Secure, clean and efficient
energy
Smart, green and integrated
transport
Climate action, resource
efficiency and raw materials
Inclusive, innovative and
reflective societies
Security society
European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
3
Coverage of the full innovation chain
Societal challenges
Industrial leadership
Excellent science
Basic
Research
Demonstration
Technology
R&D
Prototyping
Large scale
validation
Pilots
Market
uptake
FP7 Health (2007-2013):
first outcomes
Key figures
First outcomes
(on 319 closed projects)
5.4 b€ invested
10,200 publications
1,052 projects
32 publications per project
11,900 teams
3,500 organisations
130 countries
3.2 average SJR*
200 patent applications
30 spin-offs created
* SCImago Journal Ranking
Health in Horizon 2020
Pillar 3: Societal Challenge
Health, demographic change
and wellbeing
R&I
action
s
7.4 b€
IMI-2
Pillar 2: Industrial leadership
LEIT
Biotech
Pillar 1: Excellent science
ERC
Fast
track
EDCTP2
PPI
Risk
finance
FET
JP
AA
L
EI
P
SME
instrumen
t
Marie SkłodowskaCurie
EIT
ERA NET
Eureka
Eurostars
Infrastructures
Budget for the 3 pillars in %
7
Budget in the 3 pillars
Excellent Science
Societal
challenges
Industrial Leadership
Budget from FP1 to Horizon 2020
Programmi Quadro
quadriennali e quinquennali
Programmi Quadro
settennali.
TOP DOWN OR BOTTOM UP
Health, demographic change
and wellbeing
TOP DOWN
BOTTOM
UP
TOP DOWN
BOTTOM
UP
(SME)
Food security, sustainable
agriculture, marine and
maritime research & the
bioeconomy
TOP Secure, clean andDOWN
efficient
energy
Smart, green and integrated
transport
BOTTOM
Climate
UP action, resource
efficiency and raw materials
(SME)
Inclusive, innovative and
reflective societies
Security society
European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
10
3° PILLAR
SOCIETAL CHALLENGES
11
STRATEGIC INITIATIVES
Innovative Medicines Initiative 2
www.imi.europa.eu
Active and Assisted Living 2
www.aal-europe.eu
European Innovation Partnership
on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha
European & Developing Countries
Clinical Trials Partnership (EDCTP2)
www.edctp.org
Struttura del programma
Health, demographic change
and wellbeing
Food security, sustainable
agriculture, marine and
maritime research & the
bioeconomy
Secure, clean and efficient
energy
Smart, green and integrated
transport
Climate action, resource
efficiency and raw materials
Inclusive, innovative and
reflective societies
Security society
European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
13
Healthcare opportunities:
making medical treatments more personalised
• Avalanche of new –omics and molecular information following the sequencing
of the human genome
• Translation of – omics from basic to clinical research can bring us better
understanding of health and disease
Clinical
definition
of disease
Molecular
definition
of disease
Molecular
definition
of health
• Need innovative approaches for changing the focus from treatment and cure to
prediction and prevention
Personalised Medicine
Workshops & conference
• Vision for Europe 2020: identify bottlenecks for PM implementation into
clinical practise
• 2010: Preparatory workshops (-omics, biomarkers, clinical trials/regulatory,
uptake)
• 2011: European Perspectives in PM conference
Available on:
http://ec.europa.eu/research/health
Challenges in SC 1.
Personalised Medicine: a novel approach with many
challenges along the way.
R&D
the basics
“Omics”
Technologies
R&D
stratifying
tools
Biomarkers
Identification
Qualification
Validation
Data
Samples
Statistics
Data modelling
tools
Technical
aspects &
challenges
R&D
test in
human
Clinical trials
Methodologies
Ethics
Patient recruitment
Towards
the market
Uptake in
healthcare
Diagnostics &
Therapies
Pricing &
Reimbursement
Approval
processes
Health economy
HTA
Regulatory
aspects
Novel models of
healthcare
organisation
Prediction - Prevention – Treatment - Cure
In patients
Availability &
usability in
the clinic
Patient
perspective
Equal
treatment
Training of
professionals
1. HEALTH,
DEMOGRAPHIC
CHANGE
AND
WELLBEING
17
Pers. Health and Care
Broad topics
Less prescriptive topic texts
Two-year work programme
Stronger focus on end users
Clinical trials
Personalised medicine – towards a definition
"Personalised medicine refers to a medical model using
molecular profiling for tailoring the right therapeutic strategy
for the right person at the right time, and/or to determine the
predisposition to disease and/or to deliver timely and targeted
prevention"
International cooperation in H2020:
General opening
•
Horizon 2020 is open to participation from across the
world
•
Automatic funding:
•
•
Member States (including overseas departments and
overseas territories)
•
Associated Countries
•
exhaustive list of countries in annex to work
programme (but: no longer BRIC + Mexico in this list!)
Participants from other countries only funded in
exceptional cases:
•
when provision is made in the call text
•
bilateral agreement (e.g. Health challenge – NIH)
•
when the Commission deems it essential (case by case
assessment)
The Horizon 2020 societal challenge of ‘Health, Demographic change and
Wellbeing’ (SC1) for the years 2014 and 2015
Includes 36 topics in the ‘personalising health and care’ focus area call, and 15 topics in the
‘co-ordination activities’ call.
The total budget available is approximately EUR
1.20bn.
Topics in the call are divided into 7 areas.
Societal challenge 1 is also implemented by the Innovative Medicines Initiative (IMI), the
European and Developing Countries Clinical Trials Partnership (EDCTP), the Active and
Assisted Living programme (AAL) and the European Innovation Partnership on Active and
Healthy Ageing (EIP-AHA).
Many topics will be evaluated in two stages. Exceptions to the two stage approach
include a number of ‘close to market’ type topics, including those which make use of the
SME instrument.
The 2014 topics deadlines are as follows:
Two stage calls:
•
Stage 1 – 11 March 2014
•
Stage 2 – 19 August 2014
One stage calls: 15 April 2014
The 2015 topics deadlines are as follows:
Two stage calls:
• Stage 1 – 14 October 2014
• Stage 2 – 24 February 2015
One stage calls: 21 April 2015
21
7 Focus Areas
Understanding health, ageing & disease
Effective health promotion, disease prevention,
preparedness and screening
Improving diagnosis
Innovative treatments and technologies
Advancing active and healthy ageing
Integrated, sustainable, citizen-centred care
Improving health information, data exploitation and
providing an evidence base for health policies and regulation
Understanding the call topics: example
• 'PHC 2 – 2015'
• 'Specific challenge'
• 'Scope'
• 'Expected impact'
• 'Type of action'
Understandin
g health, agein
g & disease
Unravelling health and disease
•
Determinants, risk factors and pathways of diseases (2014)
(PHC 1)
Determinants and pathways of healthy and active ageing
(2014) (PHC 1)
•
Systems medicine approaches (2015) (PHC 2)
•
Common mechanisms of diseases and potential co-morbidities
(2015) (PHC 3)
Effective healt
h promotion,
disease
prevention, p
reparedness a
nd screening
From "omics" … to prevention
•
Inter-sector cooperation for environment- and healthbased interventions (2015) (PHC4)
•
Translating -omics into stratified prevention and health
promotion (2014) (PHC 5)
•
Evaluating existing screening and prevention programmes
(2014) (PHC 6)
•
Control of infectious epidemics through rapid pathogen
identification (2014) (PHC 7) (see also SC2)
•
Vaccine platforms for TB (2014) (PHC 8) and HIV (2015)
(PHC9)
Improving dia
gnosis
In biomarkers we trust …
and in novel diagnostic tools
•
In vitro devices, assays and platforms (2014) (PHC 10)
•
In vivo medical imaging technologies (2015) (PHC 11)
•
Clinical validation of biomarkers (2014, 2015) (PHC 12)
SME type of action
Innovative tr
eatments nd
technologies
a
Finding the cure …
and evaluating existing treatments
•
Therapies for non-communicable diseases (2014) (PHC 13)
and rare diseases (2015) (PHC 14)
•
Clinical research on regenerative medicine (2014) (PHC15)
•
Tools and technologies for advanced therapies (2015)
(PHC 16)
•
Comparing and establishing effectiveness of health
interventions in the elderly (2014) (PHC 17) and in
paediatric population (2015) (PHC 18)
Advancing ac
tive and healt
hy ageing
Adding more life to our years
•
Service robotics within assisted living environments (2014)
(PHC 19*)
•
Pilot projects on independent living with cognitive
impairments (2014) (PHC 20*) (Innovation type of action)
•
Early risk detection and intervention (2015) (PHC 21*)
•
Promoting mental wellbeing in the ageing population (2015)
(PHC 22)
* Topics with ICT focus
Integrated, s
ustainable,
citizen-centre
d care
The citizen in the centre
•
New models for prevention oriented health and care
systems (2014) (PHC 23)
•
Piloting personalised medicine in health and care systems
(2015) (PHC 24)
•
Self-management of health and disease:
•
citizen engagement and mHealth for disease management
(2014), (PHC 26*)
•
patient empowerment supported by ICT (2015) (PHC 27*)
•
based on predictive computer modelling (2015) (PHC28*)
* Topics with ICT focus
Integrated, s
ustainable,
citizen-centre
d care
The citizen in the centre (2)
•
Public procurement of innovative eHealth services
(2015) (PHC 29*)
•
ICT systems for integrated care (2015) (PHC 25*)
•
eHealth sectorial inducement prize (2015)
* Topics with ICT focus
Big Data for research
Improving he
alth informati
on,
data exploita
tion and prov
iding an
evidence ba
se for health polic
ies
and regula
tion
•
Digital representation of health data to improve diagnosis and
treatment (2015) (PHC 30*)
•
Foresight for health policy development and regulation
(2014) (PHC 31)
•
Advancing bioinformatics for clinical needs (2014) (PHC 32)
•
Improve predictive human safety testing (2015) (PHC 33)
•
eHealth interoperability (2014) (PHC 34*)
Call for Co-ordination activities 2014-2015
1.1. EIP on AHA – European Innovation Partnership on Active and
Healthy Ageing
1.2. JPI – Joint Programming Initiative More Years and Better Lives
1.3. European Reference Networks: Efficient network modelling and
validation
1.4. Global Alliance for Chronic Diseases: prevention and treatment
of type 2 diabetes
1.5. ERA-NETs
- Synergies between JPND (Neurodegenerative Diseases) and H2020
- Cancer Research
- Brain related diseases
- Systems medicine for clinical needs research
- Rare Diseases research implementing IRDiRC objectives
32
Personalised medicine in Europe
www.geenivaramu.ee
www.cancerresearchuk.org
www.imtm.cz
www.medizin.uni-greifswald.de/GANI_MED
French National Cancer Institute
(INCA)
Economic impact of molecular testing
Cancer
Drug
lung
cancer
gefitinib
colorectal
cancer
erlotinib
cetuximab
Panitumumab
%
Nb of
Number of Median PFS
Cost of
patients
Biomarker
tested
spared
for non
treatment/
with
patients prescriptions responders
patient
mutation
EGFR
mut
KRAS
mut
10,3%
36%
16722
17250
15000
8 weeks
15000
8 weeks
4 600 €
8 months 32 419 €
8 weeks
9 263 €
6 210
4 weeks
4 600 €
4 390 €
Spared cost
Public fundings
allocated for the
provision of the
test
€69 M
€1.7 M
€ 201 M
€57 M
€2.5 M
€27 M
www.e-cancer.fr
Source: F. Calvo presentation 13-05-2011
www.healthcompetence.eu
Progetti finanziati nel settore Health
nel vi e vii PQ.
36
37
38
39
Struttura del programma
Health, demographic change
and wellbeing
Food security, sustainable
agriculture, marine and
maritime research & the
bioeconomy
Secure, clean and efficient
energy
Smart, green and integrated
transport
Climate action, resource
efficiency and raw materials
Inclusive, innovative and
reflective societies
Security society
European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
40
H2020:
HEALTH-RELATED TOPICS IN OTHER WORK PROGRAMMES
41
42
43
44
45
46
H2020 - Competitive Industries
“health” is mentioned as one of
the potential application
areas to demonstrate the
results of research performed
Six main activity lines have been identified in the ICTLEIT part of the Work Programme 2014 - 2015:
1. A new generation of components and systems
2. Advanced Computing
3. Future Internet
4. Content technologies and information management
5. Robotics
6. Micro- and nano-electronic technologies, Photonics
+
- ICT Cross cutting activities
- ICT Innovation Actions
Call 2015
48
FP7 support to Life Sciences Infrastructures
(early 2013)
red/purple:
ESFRI
projects;
ISBE,
blue:
Integrat. activities
AnaEE
green:
e-infrastructures
http://www.eurorisnet.eu/transnational-access-calls
NCP network
New website!
Transnational Access open calls/e-infrastructures services: One-stop shop
http://www.euroris-net.eu/
transnational-access-opportunities
PRACE Partnership for Advanced Computing in Europe
Biobanking and Biomolecular Resources
Research Infrastructure
European Advanced Translational
Research Infrastructure in Medicine
European Clinical Research
Infrastructures Network ***
European Life Science Infrastructure
for Biological Information
European Marine Biology Resource
Centre
European Research Infrastructure on
Highly Pathogenic Agents
Prossime CALL 2013
The IMI 11th Call 2013 for proposals includes a topic covering
the following key research priority:
- Applied public-private research enabling osteoarthritis clinical headway .
- European platform for proof of concept for prevention in Alzheimer’s Disease .
- Blood-based biomarker assays for personalised tumour therapy: value of latest
circulating biomarkers .
- Zoonoses anticipation and preparedness initiative.
-Generation of research tools to translate genomic discoveries into drug
discovery projects.
- EcoRisk Prediction.
IMI 11th Call
Publication date:
11 Dicembe 2013
Deadline:
8 Aprile 2014
Topics under the New Drugs for Bad Bugs (ND4BB) programme on antimicrobial
resistance:
- Epidemiology research and development of novel systemic antibacterial
molecules against healthcare-associated infections due to Gram-negative
pathogens
-Development of novel inhaled antibiotic regimens in patients with cystic
fibrosis (CF) and patients with non-CF bronchiectasis (BE)
IMI Partner Search Tool
http://www.imi.europa.eu/content/future-topics
53
• IMI è una partnership pubblico-privata che unisce la
Commissione Europea e la Federazione delle
Industrie Farmaceutiche Europee (EFPIA)
• IMI è stata creata allo scopo di finanziare la ricerca
collaborativa
pre-competitiva
nel
campo
dell’efficienza e sicurezza dei farmaci indirizzati ad
un ristretto nucleo di patologie
54
Funding rates are the following
(only for beneficiaries):
-Research activities: a maximum of 75% of total eligible costs.
-Other activities, including management and training activities: a
maximum of 100% of total eligible costs.
Indirect costs
- actual indirect cost.
- or a flat rate of 20% of total eligible direct costs (excluding
subcontracting costs and the costs of resources made available by
third parties which are not used on the premises of the beneficiary)
for organisations which do not aggregate their indirect costs at a
detailed level, but can aggregate them at the level of the legal
entity.
Ageing well – the EU picture
Active and Healthy Ageing EIP
New
Knowledge
Proven
Ideas
New solutions Evidence
and
innovation
guidelines
Deployment support
JPIs
More Years Better Lives
Alzheimer’s
Horizon 2020
Horizon
2020
Health
Structural
Funds
EIB
ESF
eHealth
eHealth
ICT &
Ageing
Research
Public Health
Programme
AALn JP
V2
Innovation
EIT-KIC
Deployment
Further Information
•
Digital Agenda for Europe
http://ec.europa.eu/digital-agenda
•
•
ICT Policy Support Programme
http://ec.europa.eu/ict_psp/
Ambient Assisted Living Joint Programme
http://www.aal-europe.eu/
•
JPI - More Years – Better Lives
http://www.jp-demographic.eu
•
Active and Healthy Ageing Partnership
•
http://ec.europa.eu/active-healthy-ageing
Contact:
CNECT-ICT4ageing (at) ec.europa.eu
••• 57
Criteri di valutazione e struttura
di una propostaH2020 nelle SC e
LEITs
CRITERI DI SELEZIONE E ATTRIBUZIONE (Art. 15)
3 CRITERI
POSSIBILI BANDI CON PROCEDURA DI PRESENTAZIONE A DUE STEP
ECCELLENZA, UNICO CRITERIO PER LE AZIONI ERC
PESO PONDERATO CRITERIO ‘IMPATTO’ NELLE INNOVATION ACTION
Calls
HORIZON 2020 CALLS
FUNDING GUIDE
Horizon 2020
COSME
66 results
Filter options
Search Topics
Call Updates
Other Funding Opportunities
Type:
Calls for proposal
Calls for tender
Specific Programme:
Excellent Science
Industrial Leadership
Societal Challenges
Spreading excellence and widening participation
Science with and for society
Status:
Open calls
○ Closed calls
○ Forthcoming calls
Previous Framework
Programmes (FP7 & CIP)
Sort by:
Stay informed
RSS feed
iCal
Email notification
Publication date
○ Deadline
○ Title
○ Call ID
ONLINE SUBMISSION
FORMS
PROPOSAL
PART A
Administrative
PART B
Technical
Single stage SC 1
(Deadline: 15th April 2014)
PARTE B
PARTE A
1) Excellence
1)General Information
1.1) Objectives
1.2)Relation to the Work Programme
1.3) Concept and Approach
1.4) Ambition
2) Impact
2)Participants & Contacts
3)Budget
4)Ethics
2.1) Expected impacts
2.2) Measures to maximize the impact
- Dissemination and
exploitation of results
- Communication
activities
3) Implementation
3.1) Work plan — Work packages,
deliverables and milestones
3.2) Management structure and procedures
3.3) Consortium as a whole
3.4) Resources to be committed
4) Members of the consortium
Template pdf online sul Participant Portal
4.1) Participants (applicants)
4.2) Third parties involved in the project
(including use of third party resources)
5) Ethics and Security
Documento Word scaricabile dal Participant Portal
Max. 70 pages!
62
Consigli
• Far riferimento alla propria rete di contatti per la
partnership/investire in visibilità del team
• Costruire un progetto «multidiscilinare» e
transettoriale/trasferibilità
• Rafforzare il coinvolgimento attivo degli utilizzatori finali.
• Coinvolgimento dell’industria (PMI o grande) a cui affidare
l’avvicinamento al Mercato
• Curare minuziosamente l’impatto sul mercato, sulla società,
sul settore scientifico e clinico, l ‘innovazione.
• Far rileggere le proposte in bozza ai NCP per avere
commenti strutturale e migliorare la chiarezza e la
coerenza.
64
PARTICIPANT PORTAL
ECAS ACCOUNT
PARTICIPANT PORTAL
PIC
Codice Identificativo del Partecipante (9 CIFRE) cui sono associati i dati
amministrativo-finanziari
(dati amm.vi dell’ente, status giuridico, metodo di calcolo dei costi indiretti, etc…)
Si ottiene tramite registrazione online tramite la cd. Unique Regitration Facility, ospitata dal
Participant Portal:
https://ec.europa.eu/research/participants/portal//desktop/en/organisations/register.html
Presuppone validazione dell’ente da parte della CE
Obbligatorio in fase di negoziazione
I dati associati al PIC possono essere modificati/aggiornati solo tramite il LEAR (Legal Entity
Authorized Representative)
PART A
Administrative
PART B
Technical
H2020 - PARTICIPATION RULES –
MAIN ELEMENTS
68
SOGGETTI GIURIDICI PARTECIPANTI (art.7)/ ELEGGIBILITA’ PER IL FINANZIAMENTO (art.10)
CHI PUO’ PARTECIPARE?
Qualsiasi soggetto giuridico, universita’ o
centro di ricerca stabilito in uno stato membro
o associato* o in un paese terzo
JRC (Joint Research Centre)
CHI PUO’ RICEVERE
IL FINANZIAMENTO?
Qualsiasi soggetto giuridico, universita’ o
centro di ricerca stabilito in uno stato membro
o associato o in un paese terzo
JRC (Joint Research Centre)
Paesi ICPC
Organizzazioni internazionali di interesse EU
Organizzazioni internazionali di interesse EU
Organizzazioni internazionali e soggetti stabiliti
in paesi terzi in aggiunta alle condizioni minime
*Albania, Bosnia-Herzegovina, CroaZia, FYR Macedonia, Islanda,
Israele, Liechtenstein, Montenegro, Norvegia, Serbia, Turchia (DA
CONFERMARE)
Organizzazioni internazionali e soggetti stabiliti in
paesi terzi non ICPC solo eccezionalmente se
previsto dal WP/accordo bilaterale oppure se
essenziale per l’azione
POSSIBILITA’ DI JOINT CALL CON I PAESI TERZI E LE ORG. INTERNAZIONALI
 APRE 2013
PAESI ELEGGIBILI
PAESI TERZI
SVIZZERA EQUIPARATA A PAESI TERZI INDUSTRIALIZZATI: NO FINANZIAMENTO AUTOMATICO
 APRE 2013
CONDIZIONI MINIME DI PARTECIPAZIONE (art.9)
3 SOGGETTI GIURIDICI indipendenti stabiliti in
3 diversi stati membri o associati
1 SOLO PARTECIPANTE
ERC, SME Instrument, Azioni Co-fund, CSA, Azioni A
Supporto Della Mobilita’ E Della Formazione Dei
Ricercatori(marie Curie)
CONDIZIONI AGGIUNTIVE: possono essere previste nel work programme
(n. di partecipanti, tipologie di partecipanti, etc…)
 APRE 2013
WHICH TYPE OF ACTIONS AND
FUNDING %
72
Azioni
AZIONE DI RICERCA E INNOVAZIONE
(RESEARCH AND INNOVATION ACTION)
AZIONE DI INNOVAZIONE
(INNOVATION ACTION)
AZIONE DI COORDINAMENTO E SUPPORTO
(COORDINATION AND SUPPORT ACTION)
ERANET CO-FUND
(PROGRAMME CO-FUND)
 APRE 2013
DEFINIZIONI (art.2)
UNICA % DI RIMBORSO PER PROGETTO
RESEARCH AND INNOVATION
ACTION (RIA)
attività di ricerca, sviluppo
tecnologico, dimostrazione e
innovazione, comprese la
promozione della cooperazione con i
paesi terzi e le organizzazioni
internazionali, la diffusione e
l'ottimizzazione dei risultati nonché la
promozione della formazione di
elevata qualità e della mobilità dei
ricercatori nell'Unione
fino al 100% dei
costi eleggibili
COORDINATION AND
SUPPORT ACTION (CSA)
Standardizzazione, diffusione,
sensibilizzazione e comunicazione,
collegamento in rete, studi di
apprendimento reciproco, dialoghi
in materie di politiche
 APRE 2013
DEFINIZIONI (art.2)
NEW
INNOVACTION ACTION (IA)
Attività di creazione di prototipi,
collaudo, dimostrazione, progetti
pilota, convalida dei prodotti su larga
scala e prime applicazioni
commerciali, per prodotti, processi o
servizi nuovi, modificati o migliorati
UNICA % DI RIMBORSO PER
PROGETTO
fino al 70% dei costi eleggibili
(fatta eccezione per organismi no-profit,
finanziabili fino al 100%)
 APRE 2013
SME INSTRUMENT (art.53)
INNOVATION ACTION – PROCEDURE SPECIFICHE
A. STRUMENTO
PMI
• SOLO PER PMI (1 PMI o consorzio di PMI)
• APPROCCIO BOTTOM UP (più o meno generico) nei SC/LEIT
• OPEN CALL, organizzate in 3 FASI
1. lump sum per esplorare la fattibilità e il potenziale commerciale
dell’idea progettuale
2. Grant per attività di R&I con focus sulle attività dimostrative
3. Misure di supporto e attività di networking per lo sfruttamento
dei risultati
• Nessun obbligo per i partecipanti di coprire tutte e tre le fasi
• Combinanzione di attività di dimostrazione (test,
prototipizzazione, …), e ricerca
• Gestione centralizzata (EACI)
 APRE 2013
INNOVATION ACTION - PROCEDURE
B. STRUMENTO
PMI
Pre-Commercial
Procurement
SME window EU
financial facilities
Idea to concept,
risk assessment,
technological & commercial
feasibility
Lump sum: 50.000 €
1-3 (5) M€ contributo CE
~ 6 mesi
~ 12 to 24 mesi
Idea
Quality label for
successful projects,
access to risk finance,
indirect support
Demonstration, prototyping,
testing , market replication,
scaling up, miniaturisation,
research
Nessun finanziamento diretto
Sostegno continuo per l'intera durata
Mercato
 APRE 2013
STRUMENTO PMI
ESEMPIO
FINANZIAMENTO 70%
(predominante attività dimostrativa)
FINANZIAMENTO 100%
(predominante attività di ricerca)
 APRE 2013
COSTI INDIRETTI (Art. 29)
NEW
STANDARD FLAT RATE (20%)
SPECIAL FLAT RATE (60%)
SIMPLIFIED METHOD or
ACTUAL INDIRECT COSTS
UNICO TASSO FORFETARIO DEL
25% DEI COSTI DIRETTI
(ECCETTO I SUBCONTRATTI E COSTI
DELLE RISORSE MESSE A
DISPOSIZIONE DA TERZI CHE NON
VENGONO UTILIZZATE NEI LOCALI
DEL BENEFICIARIO, NONCHÉ DEL
SOSTEGNO FINANZIARIO A TERZI)
 APRE 2013
FINANZIAMENTO DELL’AZIONE (Art. 28)
UNICA % DI RIMBORSO PER NEW
PROGETTO, SENZA DISTINZIONE
TRA BENEFICIARI
•fino al 100% dei costi eleggibili per
progetti R&S (cd. RESEARCH &
INNOVATION action)
• fino al 70% per progetti dimostrativi
cd. INNOVATION action (fatta
eccezione per organismi no-profit,
finanziabili fino al 100%) e CO-FUND
 APRE 2013
EXAMPLE: In FP7, around 90 % of the Universities and more than a half of the Research
Organisations apply the 60 % flat-rate for indirect costs. For all these participants the
impact on the EU contribution of the H2020 funding model will be favourable:
Flat-rate (60 %)
100 / 25 Funding
Direct
costs
Indirect
costs
Total
costs
100
60
160
Direct
costs
Indirect
costs
100
25
% EU
EU
contribution contribution
75%
€ 120
Total
% EU
EU
costs contribution contribution
125
100%
€ 125
A chi rivolgersi per un supporto?
+
Punti di Contatto Nazionali (APRE)
Informazioni pratiche & consigli sulle procedure e regole di
partecipazione
National delegates in Programme Committees
Interpretazione scientifica dei bandi, input all’elaborazione dei
Work Programme
European Enterprise Networks (EEN)
EC Information desks (contattabili via e-mail o telefono)
82
LINK UTILI
•Participant Portal
•http://ec.europa.eu/research/participants/portal/desktop/en/home.html
•ECAS account creation
•https://webgate.ec.europa.eu/cas/eim/external/register.cgi
•FAQ
•http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html
•FITFORHEALTH: ricerca partner
•http://mm.fitforhealth.eu/common/contactslogin.asp
•HEALTH2MARKET: assistenza a portare i risultati della ricerca al mercato.
•http://www.health2market.eu/
www.HealthCompetence.eu
An open, pan-European infrastructure
for information on research projects &
results within Health Science
84
http://www.health2market.eu/
85
GRAZIE PER L‘ATTENZIONE!
APRE
Agenzia per la Promozione della Ricerca Europea
via Cavour, 71
00184 - Roma
www.apre.it
Tel. (+39) 06-48939993
Fax. (+39) 06-48902550
Caterina Buonocore
Health NCP
[email protected]
86
Author
Document
Category
Uncategorized
Views
1
File Size
5 418 KB
Tags
1/--pages
Report inappropriate content